These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23315343)

  • 1. Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study.
    Bytzer P; Pratt S; Elkin E; Næsdal J; Sörstadius E
    Am J Cardiovasc Drugs; 2013 Feb; 13(1):27-35. PubMed ID: 23315343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk.
    Pratt S; Thompson VJ; Elkin EP; Næsdal J; Sörstadius E
    Am J Cardiovasc Drugs; 2010; 10(5):281-8. PubMed ID: 20666569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.
    Scheiman JM; Herlitz J; Veldhuyzen van Zanten SJ; Lanas A; Agewall S; Nauclér EC; Svedberg LE; Nagy P
    J Cardiovasc Pharmacol; 2013 Mar; 61(3):250-7. PubMed ID: 23188121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic Acid: a quantitative study in patients with cardiovascular risk.
    Moberg C; Naesdal J; Svedberg LE; Duchateau D; Harte N
    Patient; 2011; 4(2):103-13. PubMed ID: 21766899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The aspirin cardiovascular/gastrointestinal risk calculator--a tool to aid clinicians in practice.
    Lanas A; Polo-Tomás M; Casado-Arroyo R
    Aliment Pharmacol Ther; 2013 Apr; 37(7):738-48. PubMed ID: 23413984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.
    Saini SD; Fendrick AM; Scheiman JM
    Aliment Pharmacol Ther; 2011 Jul; 34(2):243-51. PubMed ID: 21615437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment.
    Lanas A; Scheiman J
    Curr Med Res Opin; 2007 Jan; 23(1):163-73. PubMed ID: 17257477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of low-dose aspirin on the decreased risk of development of dyspepsia and gastrointestinal ulcers associated to cyclooxygenase-2 selective inhibitors.
    Benito-Garcia E; Michaud K; Wolfe F
    J Rheumatol; 2007 Aug; 34(8):1765-9. PubMed ID: 17611980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
    Goldstein JL; Bello AE; Spalding W; Suh S; Fort JG
    J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation.
    Herlitz J; Tóth PP; Naesdal J
    Am J Cardiovasc Drugs; 2010; 10(2):125-41. PubMed ID: 20334450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
    Rostom A; Moayyedi P; Hunt R;
    Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United kingdom primary care.
    Martín Merino E; Johansson S; Nagy P; García Rodríguez LA
    Am J Cardiol; 2013 Oct; 112(8):1075-82. PubMed ID: 23831164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
    Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
    Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies.
    Pilotto A; Franceschi M; Leandro G; Di Mario F;
    Drugs Aging; 2003; 20(9):701-10. PubMed ID: 12831293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolic acid (cellcept and myofortic) induced injury of the upper GI tract.
    Nguyen T; Park JY; Scudiere JR; Montgomery E
    Am J Surg Pathol; 2009 Sep; 33(9):1355-63. PubMed ID: 19542873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroprotection in low-dose aspirin users for primary and secondary prevention of ACS: results of a cost-effectiveness analysis including compliance.
    de Groot NL; van Haalen HG; Spiegel BM; Laine L; Lanas A; Focks JJ; Siersema PD; van Oijen MG
    Cardiovasc Drugs Ther; 2013 Aug; 27(4):341-57. PubMed ID: 23417566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
    Targownik LE; Metge CJ; Leung S; Chateau DG
    Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events.
    Zhang W; Han Y; Fort JG; Schofield D; Tursi JP
    J Med Econ; 2017 Jun; 20(6):592-598. PubMed ID: 28145783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.